Despite the effectiveness of aromatase inhibitors and selective estrogen receptor (ER) modulators in averting metastatic recurrence of BC, their benefits are limited to ER+ BC and their side effects make them less than desirable for long‐term use (Patel & Bihani, 2018). The gene discussed is ESR1; the disease is breast cancer.